Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Cystic fibrosis

Last updated: February 26, 2021

Summarytoggle arrow icon

Cystic fibrosis (CF) is an autosomal recessive disorder caused by a mutation in the CFTR gene, which encodes for the cystic fibrosis transmembrane conductance regulator protein. The mutation leads to the production of defective chloride channels in cell membranes of the exocrine glands, and symptoms are caused by these glands producing abnormally hyperviscous secretions. Failure to pass meconium (meconium ileus) is often the first clinical sign of cystic fibrosis. Later, the lungs, digestive system, and sweat glands are commonly affected. Bronchial accumulation of hyperviscous mucus and impaired ciliary clearance predispose affected individuals to chronic respiratory infection, pulmonary colonization with multiresistant bacteria, and long-term complications such as emphysema. Impaired secretion of pancreatic and biliary juices leads to digestive problems and chronic organ damage. The sweat test (pilocarpine iontophoresis) is considered the gold standard for detecting elevated levels of chloride in sweat, which is a characteristic sign of cystic fibrosis. The mainstay of treatment is symptomatic management. More recently, however, the development of CFTR-modulators has provided a causal approach for individuals with certain specific mutations. The median life expectancy is 39 years. Complications of chronic lung disease are the leading cause of death.

  • Second most common genetic metabolic disorder; after hemochromatosis in individuals of Northern European descent. [1][2][3]
  • Incidence: approx. 1:3,500 in the US [4]

Epidemiological data refers to the US, unless otherwise specified.

Children whose parents are both heterozygous carriers of cystic fibrosis have a 25% chance of being affected by the condition.

  • General considerations
  • In sweat glands
    • The chloride channel is responsible for transporting Cl- from the lumen into the cell (reabsorption).
    • Defective ATP-gated chloride channel inability to reabsorb Cl- from the lumen of the sweat glands → reduced reabsorption of Na+ and H2O → excessive loss of salt and elevated levels of NaCl in sweat
  • In all other exocrine glands (e.g., in the GI tract or lungs)
    • The chloride channel is responsible for transporting Cl- from the cell into the lumen (secretion).
    • Defective ATP-gated chloride channel inability to transport intracellular Cl- across the cell membrane → reduced secretion of Cl- and H2O → accumulation of intracellular Cl- ↑ Na+ reabsorption (via ENaC) ↑ H2O reabsorption formation of hyperviscous mucus accumulation of secretions and blockage of small passages of affected organs → chronic inflammation and remodeling → organ damage (see “Clinical features” below)
    • ↑ Na+ reabsorption → transepithelial potential difference between interstitial fluid and the epithelial surface increases; (i.e., negative charge increases; e.g., from normal -13 mv to abnormal -25 mv)

Gastrointestinal [8]

Gastrointestinal symptoms are common in children. The presence of these features during infancy should raise suspicion for CF.

In almost all cases of meconium ileus, cystic fibrosis is the underlying disease.

Respiratory [8]

Respiratory symptoms are common in adulthood. CF should be considered in individuals with the following features:

Sweat glands

  • Particularly salty sweat
  • Possible electrolyte wasting

Musculoskeletal

Urogenital

General

  • CF should be suspected in the presence of clinical features, positive newborn screening, or positive family history.
  • Neonatal screening is routinely performed in all US states.
  • Best initial test is the sweat chloride test.
    • If results are abnormal or borderline, DNA testing for the two CFTR mutations is indicated to confirm the diagnosis.
    • If only one or no CFTR mutations are identified, an expanded DNA analysis or second sweat test should be performed; a positive result for either one of these tests confirms the diagnosis.
  • Carrier screening is recommended in women with a family history of CF who wish to conceive.

Diagnostic criteria [12]

The criteria for diagnosing CF are: .

Neonatal screening [12][13]

A positive NBS test result alone does not confirm CF diagnosis and should quickly be followed by further diagnostics.

  • Immunoreactive trypsinogen (IRT)
    • Usually the first screening assay performed on neonates via blood spot (heel-prick)
    • Detects elevated levels of IRT
  • DNA assay
    • Either primary screening test or confirmation of CF after abnormal IRT result
    • Identification of common CFTR mutations

CF screening is routinely performed in the US.

Laboratory tests [14]

  • Sweat test (quantitative pilocarpine iontophoresis): best initial test
    • Method: The chloride concentration in the sweat is measured following chemical stimulation of the sweat glands with pilocarpine.
    • Interpretation
      • A chloride concentration ≥ 60 mmol/L indicates a likely diagnosis of cystic fibrosis.
      • Chloride concentrations between 30–59 mmol/L are considered intermediate range and require genetic analysis to either rule out or confirm CF diagnosis.
      • A chloride concentration < 30 mmol/L implies that CF is unlikely.
    • The test should be conducted in patients > 2 weeks of age and > 2 kg in weight.
  • DNA analysis
  • Nasal potential difference test
    • Indication: unclear findings in sweat and DNA tests despite the presence of typical clinical features of CF
    • Voltage measurements before and after the nose is perfused with different solutions show abnormal epithelial secretion of chloride (e.g., more negative baseline potential difference and no difference in nasal potential difference after administration of a chloride-free solution).

In all exocrine glands, the Cl- channel is responsible for transporting intracellular Cl- across the cell membrane. However, in sweat glands, the Cl- channel is responsible for transporting Cl- from the lumen into the cell. The sweat test relies on the inability of the sweat glands to reabsorb salt, which results in elevated NaCl levels in sweat.

Supportive tests

Gastrointestinal

Respiratory

We list the most important complications. The selection is not exhaustive.

  • Median life expectancy: 39 years [20]
  • Individuals with CF who have pancreatic sufficiency tend to present with mainly pulmonary symptoms in late childhood/early adulthood and generally have a milder course of disease [21]
  • The main determinant of life expectancy is the severity of pulmonary disease: chronic respiratory infections and mucus plugging → bronchiectasis (irreversible) → progressive respiratory failure → death

Symptomatic management

CFTR modulators [22] [23]

  • Mechanism of action: CFTR modulators partially restore function of the CFTR protein.
  • Indication: Approved for patients with CF with certain mutations (e.g., the ΔF508 mutation in the CFTR gene)
  • Combination therapy: CFTR modulators act synergistically with each other to increase both the quantity and function of the CFTR protein on the cell surface, resulting in enhanced chloride transport.
  • Drugs
    • Ivacaftor
      • Increases the likelihood of the Cl- channel at the cell surface being open and thus improves Cl- transport.
      • Monotherapy for patients > 6 months of age with a G551D mutation
      • Combination therapy with either tezacaftor or lumacaftor
      • Triple-combination therapy with tezacaftor and elexacaftor
    • Lumacaftor
      • Improves the conformational stability of the defective CFTR protein, which leads to increased intracellular processing and transport of functional CFTR protein to the cell surface
      • Used in combination with ivacaftor for patients > 6 years old who are homozygous for the delta F508 mutation
    • Tezacaftor
      • Increases the amount of mature CFTR protein on the cell surface by improving intracellular processing and transport of the CFTR protein
      • Used in combination with ivacaftor for patients ≥ 6 years who are homozygous for the delta F508 mutation or a CFTR mutation responsive to the drugs
    • Elexacaftor: increases the amount of mature CFTR protein on the cell surface by improving intracellular processing and transport of the CFTR protein, works at an alternate binding site than tezacaftor on the CFTR protein

Ivacaftor increases the activity of CFTR and thereby improves Cl- transport.

Because CFTR modulators are only effective in individuals with certain CFTR mutations, it is essential to perform CFTR genotyping prior to initiating treatment.

Treatment of pulmonary infections [24][25]

Population Pathogen Antibiotic therapy
Children
Adults
  • Stenotrophomonas maltophilia
  1. Navarro S. Recopilación histórica de la fibrosis quística. Gastroenterol Hepatol. 2016; 39 (1): p.36-42. doi: 10.1016/j.gastrohep.2015.04.012 . | Open in Read by QxMD
  2. Bosch L, Bosch B, De Boeck K, et al. Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory.. BMC Infect Dis. 2017; 17 (1): p.340. doi: 10.1186/s12879-017-2448-z . | Open in Read by QxMD
  3. Sibley CD, Rabin H, Surette MG. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol. 2006; 1 (1): p.53-61. doi: 10.2217/17460913.1.1.53 . | Open in Read by QxMD
  4. The molecular genetics of cystic fibrosis. https://www.who.int/genomics/publications/reports/en/. Updated: January 1, 2004. Accessed: August 19, 2020.
  5. Maitra R, Hamilton J. Altered biogenesis of ΔF508-CFTR following treatment with Doxorubicin. Cell Physiol Biochem. 2007; 20 (5): p.465-472. doi: 10.1159/000107530 . | Open in Read by QxMD
  6. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies.. Respir Care. 2009; 54 (5): p.595-605.
  7. Tsui L-C, Dorfman R. The cystic fibrosis gene: a molecular genetic perspective. Cold Spring Harb Perspect Med. 2013; 3 (2): p.a009472-a009472. doi: 10.1101/cshperspect.a009472 . | Open in Read by QxMD
  8. Cystic Fibrosis: Does CFTR Malfunction Alter pH Regulation?. http://www.intechopen.com/books/genetic-disorders/cystic-fibrosis-does-cftr-malfunction-alter-ph-regulation-. Updated: January 9, 2013. Accessed: March 7, 2017.
  9. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32 (9): p.1626-1631. doi: 10.2337/dc09-0586 . | Open in Read by QxMD
  10. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas.. The European respiratory journal. 2001; 17 (2): p.295-301. doi: 10.1183/09031936.01.17202950 . | Open in Read by QxMD
  11. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34 (2): p.91-100. doi: 10.1002/ppul.10127 . | Open in Read by QxMD
  12. Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017; 181 : p.S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064 . | Open in Read by QxMD
  13. Diagnosis: Testing: Prenatal Screening. http://www.hopkinscf.org/what-is-cf/diagnosis/testing/prenatal-screening/. Updated: February 16, 2017. Accessed: February 16, 2017.
  14. Katkin JP. Cystic fibrosis: Clinical manifestations and diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/cystic-fibrosis-clinical-manifestations-and-diagnosis.Last updated: November 29, 2016. Accessed: February 16, 2017.
  15. Ren CL et al. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Annals of the American Thoracic Society. 2018; 15 (3): p.271-280. doi: 10.1513/annalsats.201707-539ot . | Open in Read by QxMD
  16. Ridley K, Condren M. Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. J Pediatr Pharmacol Ther. 2020; 25 (3): p.192-197. doi: 10.5863/1551-6776-25.3.192 . | Open in Read by QxMD
  17. Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.. AnnalsATS. 2014; 11 (7): p.1120-9. doi: 10.1513/AnnalsATS.201402-050AS . | Open in Read by QxMD
  18. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. AnnalsATS. 2014; 11 (3): p.425-434. doi: 10.1513/annalsats.201311-395fr . | Open in Read by QxMD
  19. Meconium ileus. https://radiopaedia.org/articles/meconium-ileus. Updated: February 16, 2016. Accessed: February 16, 2017.
  20. Neuhauser Sign (Distal Ileum). https://radiopaedia.org/articles/neuhauser-sign-distal-ileum. Updated: January 1, 2018. Accessed: February 15, 2018.
  21. Fields TM, Michel SJ, Butler CL, Kriss VM, Albers SL. Abdominal Manifestations of Cystic Fibrosis in Older Children and Adults. American Journal of Roentgenology. 2006; 187 (5): p.1199-1203. doi: 10.2214/ajr.05.0327 . | Open in Read by QxMD
  22. Laufer P, Fink JN, Bruns WT, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis.. J Allergy Clin Immunol. 1984; 73 (1 Pt 1): p.44-8.
  23. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.. Clin Infect Dis. 2003; 37 Suppl 3 : p.S225-64. doi: 10.1086/376525 . | Open in Read by QxMD
  24. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: Survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med. 2014; 161 (4): p.233. doi: 10.7326/m13-0636 . | Open in Read by QxMD
  25. Mount DB. Clinical manifestations and treatment of hypokalemia in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-treatment-of-hypokalemia-in-adults?source=search_result&search=hypokalemia&selectedTitle=1~150#H3819731.Last updated: January 7, 2016. Accessed: February 9, 2017.
  26. Herold G. Internal Medicine. Herold G ; 2014
  27. Brook I, Hinthorn DR. Chronic Sinusitis. Chronic Sinusitis. New York, NY: WebMD. http://emedicine.medscape.com/article/232791-overview#showall. Updated: March 4, 2016. Accessed: February 16, 2017.
  28. Sharma GD. Cystic Fibrosis. Cystic Fibrosis. New York, NY: WebMD. http://emedicine.medscape.com/article/1001602. Updated: June 8, 2016. Accessed: February 16, 2017.
  29. Newborn Screening for CF. https://www.cff.org/What-is-CF/Testing/Newborn-Screening-for-CF/. Updated: February 16, 2017. Accessed: February 16, 2017.
  30. Emphysema:A recent chest X-ray showed that I have hyperinflated lungs. What could cause this?. http://www.mayoclinic.org/diseases-conditions/emphysema/expert-answers/hyperinflated-lungs/faq-20058169. Updated: February 16, 2017. Accessed: February 16, 2017.
  31. Simon RH. Cystic Fibrosis: Overview of the Treatment of Lung Disease. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/cystic-fibrosis-overview-of-the-treatment-of-lung-disease.Last updated: February 13, 2017. Accessed: February 16, 2017.
  32. Dornase Alfa. https://medlineplus.gov/druginfo/meds/a694002.html. Updated: January 9, 2010. Accessed: February 16, 2017.
  33. Cunha BA. Stenotrophomonas Maltophilia. Stenotrophomonas Maltophilia. New York, NY: WebMD. http://emedicine.medscape.com/article/237024-medication. Updated: March 18, 2016. Accessed: February 16, 2017.
  34. Munoz FM. Seasonal influenza in children: Prevention with vaccines. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/seasonal-influenza-in-children-prevention-with-vaccines.Last updated: October 6, 2016. Accessed: February 16, 2017.
  35. Human Genome - Cystic Fibrosis. https://web.stanford.edu/class/psych121/humangenome-CF.htm. Updated: January 1, 2003. Accessed: February 8, 2018.
  36. Goljan EF. Rapid Review Pathology. Elsevier Saunders ; 2018
  37. McPhail GL, Clancy JP. Ivacaftor: The first therapy acting on the primary cause of cystic fibrosis. Drugs Today. 2013; 49 (4): p.253. doi: 10.1358/dot.2013.49.4.1940984 . | Open in Read by QxMD
  38. Taylor-Cousar JL et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377 (21): p.2013-2023. doi: 10.1056/nejmoa1709846 . | Open in Read by QxMD
  39. Kuk K, Taylor-Cousar JL. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. 2015; 9 (6): p.313-326. doi: 10.1177/1753465815601934 . | Open in Read by QxMD
  40. Orkambi. https://www.drugs.com/pro/orkambi.html. Updated: April 1, 2019. Accessed: July 5, 2019.
  41. Ivacaftor. https://www.drugs.com/ppa/ivacaftor.html. Updated: June 10, 2019. Accessed: July 5, 2019.
  42. Tezacaftor and Ivacaftor. https://www.drugs.com/ppa/tezacaftor-and-ivacaftor.html. Updated: March 2, 2019. Accessed: July 5, 2019.
  43. Cystic fibrosis. https://ghr.nlm.nih.gov/condition/cystic-fibrosis#. Updated: August 17, 2020. Accessed: August 19, 2020.
  44. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic Fibrosis Adult Care. Chest. 2004; 125 (1): p.1S-39S. doi: 10.1378/chest.125.1_suppl.1s . | Open in Read by QxMD
  45. Grum CM, Lynch JP 3rd. Chest radiographic findings in cystic fibrosis.. Semin Respir Infect. 1992; 7 (3): p.193-209.
  46. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing Cystic Fibrosis. Am J Respir Crit Care Med. 2011; 183 (11): p.1463-1471. doi: 10.1164/rccm.201009-1478ci . | Open in Read by QxMD
  47. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med. 2009; 180 (9): p.802-808. doi: 10.1164/rccm.200812-1845pp . | Open in Read by QxMD
  48. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med. 2013; 187 (7): p.680-689. doi: 10.1164/rccm.201207-1160oe . | Open in Read by QxMD
  49. Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016; 35 (3): p.557-577. doi: 10.1016/j.clnu.2016.03.004 . | Open in Read by QxMD
  50. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review. J Am Diet Assoc. 2008; 108 (5): p.832-839. doi: 10.1016/j.jada.2008.02.020 . | Open in Read by QxMD
  51. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr. 2008; 153 (2): p.S4-S14. doi: 10.1016/j.jpeds.2008.05.005 . | Open in Read by QxMD
  52. Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020; 19 (3): p.344-354. doi: 10.1016/j.jcf.2020.02.015 . | Open in Read by QxMD